Form 4: Akero Therapeutics COO Sells Shares to Cover Tax Obligations

Akero Therapeutics Chief Operating Officer Jonathan Young sold 1,453 shares of common stock at a weighted-average price of $54.84 to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Jonathan Young, Chief Operating Officer of Akero Therapeutics, Inc. (AKRO), sold 1,453 shares of common stock.
• The sale occurred on June 18, 2025, at a weighted-average price of $54.84 per share, with prices ranging from $54.33 to $54.84.
• The transaction was a "sell-to-cover" sale, meaning the shares were sold automatically to satisfy tax withholding obligations associated with the vesting of restricted stock units.
• This sale was not at the discretion of Mr. Young, as it was executed under the Issuer's adopted "sell-to-cover" policy.
• Following this transaction, Mr. Young directly beneficially owns 196,594 shares of common stock.
• Additionally, 60,000 shares are held indirectly in three irrevocable trusts (EA, CM, and JL Irrevocable Trusts) for the benefit of his children, for which he disclaims beneficial ownership.

Sentiment

Score: 5

Explanation: The transaction is a routine 'sell-to-cover' for tax purposes, which is a neutral event and does not indicate positive or negative sentiment regarding the company's prospects.

Positives

• The sale was a routine "sell-to-cover" transaction, indicating it was not a discretionary sale by the officer.
• The company has a clear policy for managing tax withholding obligations for restricted stock units.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The filing notes that the sales were automatic and not at the discretion of the Reporting Person, as they were executed to cover tax withholding obligations in connection with the vesting of restricted stock units under the Issuer's adopted 'sell-to-cover' policy.

Industry Context

This routine insider transaction, a 'sell-to-cover' for tax obligations, is common practice across publicly traded companies, particularly in the biotechnology sector where executive compensation often includes equity awards like restricted stock units. It does not reflect a change in the company's operational or strategic direction, nor does it provide specific insights into broader industry trends beyond standard executive compensation practices.

Comparison to Industry Standards

• This transaction is a standard 'sell-to-cover' sale, a common mechanism used by executives across various industries, including biotechnology, to satisfy tax obligations arising from the vesting of equity awards.
• It aligns with typical corporate governance practices for managing executive compensation and does not indicate any deviation from industry norms.
• No specific comparable companies or projects are relevant for this type of routine transaction.

Related Party Transactions

• 60,000 shares of common stock are held indirectly in three irrevocable trusts (EA Irrevocable Trust, CM Irrevocable Trust, and JL Irrevocable Trust) for the benefit of the Reporting Person's children, with the Reporting Person's spouse serving as trustee. The Reporting Person disclaims beneficial ownership of these securities.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes, not indicative of a change in management's confidence.
• Employees: No direct impact indicated.
• Customers: No direct impact indicated.
• Suppliers: No direct impact indicated.
• Creditors: No direct impact indicated.

Key Dates

Keywords

Akero Therapeutics, AKRO, Jonathan Young, Chief Operating Officer, Insider Trading, SEC Form 4, Stock Sale, Restricted Stock Units, Tax Withholding, Sell-to-Cover